Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment

Author(s): Petter Järemo*, Alenka Jejcic, Vesna Jelic, Tasmin Shahnaz, Magnus Oweling, Bengt Winblad, Homira Behbahani.

Journal Name: Current Alzheimer Research

Volume 16 , Issue 11 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Introduction: We recently showed that Amyloid Beta (Aβ)40 accumulates in erythrocytes and possibly causes cell damage as evidenced by an increased number of assumed injured low-density (kg/L) erythrocytes. Furthermore, we have suggested a separation technique to isolate and concentrate such damaged red blood cells for subsequent analysis.

Objectives: We isolated high- and low-density erythrocytes and investigated the accumulation patterns of the Aβ peptides (Aβ40, Aβ42, and Aβ43) in Alzheimer (AD), mild cognitive impairment (MCI), and Subjective Cognitive Impairment (SCI).

Methods: Whole blood was fractionated through a density gradient, resulting in two concentrated highand presumed injured low-density erythrocyte fractions. After cell lysis, intracellular Aβ40, Aβ42, and Aβ43 were quantified by ELISA.

Results: In both high- and low-density erythrocytes, Aβ40 displayed the lowest concentration in MCI, while it was equal and higher in AD and SCI. Aβ40 was detected at a 10-fold higher level than Aβ42, and in injured low-density erythrocytes, the lowest quantity of Aβ42 was found in AD and MCI. Aβ40 exhibited a 100-fold greater amount than Aβ43, and lighter erythrocytes of MCI subjects displayed less intracellular Aβ43 than SCI.

Conclusion: Red blood cell accumulation patterns of Aβ40, Aβ42, and Aβ43 differ significantly between AD, MCI, and SCI. The data must be verified through larger clinical trials. It is, however, tenable that Aβ peptide distributions in erythrocyte subpopulations have the potential to be used for diagnostic purposes.

Keywords: Alzheimer, amyloid-β40, amyloid-β42, amyloid-β43, erythrocytes, MCI, SCI.

[1]
Järemo P, Milovanovic M, Nilsson S, Buller C, Post C, Winblad B. Alzheimer’s disease is characterized by more low-density erythrocytes with increased volume and enhanced β-amyloid x-40 content. J Intern Med 270(5): 489-92.2011;
[http://dx.doi.org/10.1111/j.1365-2796.2011.02388.x] [PMID: 21486370]
[2]
Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ. Hemorheological mechanisms in Alzheimer’s disease. Microcirculation 14(6): 627-34.2007;
[http://dx.doi.org/10.1080/10739680701411056] [PMID: 17710633]
[3]
Mohanty JG, Eckley DM, Williamson JD, Launer LJ, Rifkind JM. Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer’s disease? Adv Exp Med Biol 614: 29-35.2008;
[http://dx.doi.org/10.1007/978-0-387-74911-2_4] [PMID: 18290311]
[4]
Carelli-Alinovi C, Dinarelli S, Sampaolese B, Misiti F, Girasole M. Morphological changes induced in erythrocyte by amyloid beta peptide and glucose depletion: a combined atomic force microscopy and biochemical study. Biochim Biophys Acta Biomembr 1861(1): 236-44.2019;
[http://dx.doi.org/10.1016/j.bbamem.2018.07.009] [PMID: 30040926]
[5]
Kosenko EA, Tikhonova LA, Montoliu C, Barreto GE, Aliev G, Kaminsky YG. Metabolic abnormalities of erythrocytes as a risk factor for Alzheimer’s disease. Front Neurosci 11: 728.2018;
[http://dx.doi.org/10.3389/fnins.2017.00728] [PMID: 29354027]
[6]
Engström I, Ronquist G, Pettersson L, Waldenström A. Alzheimer amyloid beta-peptides exhibit ionophore-like properties in human erythrocytes. Eur J Clin Invest 25(7): 471-6.1995;
[http://dx.doi.org/10.1111/j.1365-2362.1995.tb01732.x] [PMID: 7556364]
[7]
Sciacca MF, Kotler SA, Brender JR, Chen J, Lee DK, Ramamoorthy A. Two-step mechanism of membrane disruption by Aβ through membrane fragmentation and pore formation. Biophys J 103(4): 702-10.2012;
[http://dx.doi.org/10.1016/j.bpj.2012.06.045] [PMID: 22947931]
[8]
Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57(1): 100-5.2000;
[http://dx.doi.org/10.1001/archneur.57.1.100] [PMID: 10634455]
[9]
Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38(4): 643-8.1995;
[http://dx.doi.org/10.1002/ana.410380413] [PMID: 7574461]
[10]
Lauridsen C, Sando SB, Møller I, Berge G, Pomary PK1, Grøntvedt GR, et al. Cerebrospinal fluid Aβ43 is reduced in early-onset compared to late-onset Alzheimer’s disease, but has similar diag-nostic accuracy to Aβ42. Front Aging Neurosci 9(9): 210.2017;
[http://dx.doi.org/10.3389/fnagi.2017.00210] [PMID: 28701950]
[11]
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J6, Doré V, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554(7691): 249-54.2018;
[http://dx.doi.org/10.1038/nature25456] [PMID: 29420472]
[12]
Tiiman A, Jelić V, Jarvet J, Järemo P, Bogdanović N, Rigler R, et al. Amyloidogenic nanoplaques in blood serum of patients with Alzheimer’s disease revealed by time-resolved Thioflavin T fluorescence intensity fluctuation analysis. J Alzheimers Dis 68(2): 571-82.2019;
[http://dx.doi.org/10.3233/JAD-181144] [PMID: 30814355]
[13]
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256(3): 240-6.2004;
[http://dx.doi.org/10.1111/j.1365-2796.2004.01380.x] [PMID: 15324367]
[14]
Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26(3): 231-45.1995;
[http://dx.doi.org/10.1007/BF02815140] [PMID: 8748926]
[15]
Järemo P. Computerised method for recording platelet density distribution. Eur J Haematol 54(5): 304-9.1995;
[http://dx.doi.org/10.1111/j.1600-0609.1995.tb00690.x] [PMID: 7781754]
[16]
Sandebring A, Welander H, Winblad B, Graff C, Tjernberg LO. The pathogenic aβ43 is enriched in familial and sporadic Alzheimer disease. PLoS One 8(2) e558472013;
[http://dx.doi.org/10.1371/journal.pone.0055847] [PMID: 23409063]
[17]
Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H, et al. Amyloid β levels in human red blood cells. PLoS One 7(11) e496202012;
[http://dx.doi.org/10.1371/journal.pone.0049620] [PMID: 23166730]
[18]
Lauriola M, Paroni G, Ciccone FD, Onofrio G, Cascavilla L, Paris F, et al. Erythrocyte associated amyloid-β as potential biomarker to diagnose dementia. Curr Alzheimer Res 15(4): 381-5.2018;
[http://dx.doi.org/10.2174/1567205014666171110160556] [PMID: 29125073]


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 11
Year: 2019
Page: [1050 - 1054]
Pages: 5
DOI: 10.2174/1567205016666191010104355
Price: $65

Article Metrics

PDF: 20
HTML: 2